Could a new blood thinner make ECMO safer after heart surgery?
NCT ID NCT06276010
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study compares a drug called nafamostat mesilate to the standard blood thinner heparin in 80 adults who need a heart-lung machine (ECMO) after heart surgery. The goal is to see if nafamostat can prevent dangerous blood clots while causing fewer bleeding problems. Participants will be monitored for clots and bleeding events during their ECMO treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRACORPOREAL MEMBRANE OXYGENATION COMPLICATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital
RECRUITINGBeijing, Beijing Municipality, 100029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.